CDIOW Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.01 and $0.02. With a market capitalization of about $4.04 million, Cardio Diagnostics Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.18). Key stats such as the average daily volume over the past year has been around 20.12 thousand shares, volume is running light vs its 52-week average. Headquartered in Chicago, IL, Cardio Diagnostics Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Meeshanthini V. Dogan, the company employs approximately 15 people and listed since January 14, 2022. Founded in Chicago, Illinois, in 2017, Cardio Diagnostics Holdings, Inc. specializes in the creation and market introduction of clinical tests.

CDIOW has shown sold momentum, gaining 34.74% over the past week and 426.32% over the past quarter, though year-to-date performance is up 9.21%. Average 10-day trading volume of 11.68 thousand shares is significantly above the 3-month average of 7.42 thousand, indicating heightened recent market interest.

Cardio Diagnostics Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended March 13, 2026, missed forecasts by -55.56%. The prior quarter beat by -45.81%. Over the last six quarters, Apple has recorded several small beats. These include -46.13% in May 15, 2025.

Cardio Diagnostics Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.98. This means the shares are trading below this model’s fair value.

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIOW) shares are flat 9.21% year-to-date Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cardio Diagnostics Holdings, Inc. trading at a premium to the broader market with a P/E of -0.7.

Our AI price prediction model suggests that Cardio Diagnostics Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 224.68%, with price expected at $0.05 by November 24, 2023, within a range of $0.02 to $0.07

Cardio Diagnostics Holdings, Inc. trades at a P/E ratio of -0.7, slightly below the S&P 500 average, with a price-to-sales ratio of 418.73 and a price-to-book ratio of 0.81 suggesting the stock is closer to book value. The P/FCF stands at -1.04, also above market averages.